Hepatic steatosis in chronic hepatitis B: Prevalence, risk factors, and impact on fibrosis and therapeutic response

##plugins.themes.academic_pro.article.sidebar##

Published Aug 20, 2013
Download
pdf
Vol. 91 No. 7 (2013): Issue Jul 2013

##plugins.themes.academic_pro.article.main##

A. Ben Slama Trabelsi
M. Ksiaa
A. Souguir
D. Issaoui
B. Sriha
S. Ajmi

Abstract

Background: steatosis is a common injury in chronic hepatitis C, but this association has not been sufficiently studied in chronic hepatitis B.
aim: To evaluate the prevalence of hepatic steatosis in chronic hepatitis B and determine its association with various histologic, biochemical, virological, and metabolic diseases, and its effect on fibrosis and therapeutic response.
methods: Our study was compiled 133 patients with chronic hepatitis B who received no antiviral therapy and who had a liver biopsy. Our patients were divided into 2 groups: 51 patients (38.3%) had steatosis (Group I), while 82 (61.7%) had no steatosis (Group II).
results: In groupeI, the average age, BMI, cholesterol, triglycerides, and glucose were significantly higher than the group without steatosis in univariate study (P <0.05). In multivariate analysis, only high BMI and hypertriglyceridemia were included.No significant difference between the two groups was observed in the rate of transaminases, HBeAg status, viral load (P> 0.05). Steatosis doesn’t influence fibrosis stage and therapeutic response.
Conclusion: During chronic hepatitis B, steatosis appears to be the result of metabolic factors of the host rather than the effect of the virus. Hepatic steatosis does not seem to influence the progression of liver fibrosis, or therapeutic response, however, the role of steatosis should be better studied by prospective longitudinal clinical studies on large populations of patients.  

Keywords:

Steatosis, chronic hepatitis B, fibrosis, metabolic factors, treatment.

##plugins.themes.academic_pro.article.details##

References

  1. Lonardo A, Loria P, Adinolfi LE, Carulli N, Ruggiero G. Hepatitis C and steatosis: A reappraisal. J Viral Hepat 2006;3:73-80.
  2. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-64.
  3. Harrison SA. Steatosis and chronic hepatitis C infection: Mechanisms and significance. Clin Gastroenterol Hepatol 2005;3: S92-6
  4. Gordon A, McLean CA, Pedersen JS, Bailey MJ, Roberts SK. Hepatic steatosis in chronic hepatitis B and C: Predictors, distribution and effect on fibrosis. J Hepatol 2005;43:38-44.
  5. Altlparmak E, Koklu S, Yalinkilic M. Viral and host causes of fatty liver in chronic hepatitis B. World J Gastroenterol 2005;11:3056-9
  6. Thomopoulos KC, Arvaniti V, Tsamantas AC, et al . Prevalence of liver steatosis in patients with chronic hepatitis B: A study of associated factors and of relationship with fibrosis. Eur J Gastroenterol Hepatol 2006;18:233-7
  7. Bondini S, Kallman J, Wheeler A, et al. Impact of non-alcoholic fatty liver disease on chronic hepatitis B. Liver Int 2007;27:607.
  8. Tsochatzis E, Papatheodoridis GV, Manesis EK, Chrysanthos N, Kafiri G, Archimandritis AJ. Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors: A comparative approach with genotype 1 chronic hepatitis C. Dig Liver Dis 2007; 39:936-42.
  9. Lesmana LA, Lesmana CR, Pakasi LS, Krisnuhoni E. Prevalence of hepatic steatosis in chronic hepatitis B patients and its association with disease severity. Acta Med Indones. 2012;44:35- 9.
  10. Elloumi H, Hefaiedh R, Gargouri D, et al. Hepatic steatosis in chronic hepatitis B: contributing factors and effect on fibrosis. Tunis Med. 2008;86:1000-3.
  11. Rastogi A, Sakhuja P, Kumar A, et al. Steatosis in chronic hepatitis B: Prevalence and correlation with biochemical, histologic, viral, and metabolic parameters. Indian J Pathol Microbiol. 2011; 54:454-9.
  12. Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol. 2011;26:1361-7.
  13. Negro F. Mechanism and significance of liver steatosis in hepatitis C virus infection. World J Gastroenterol 2006;12:6756- 65
  14. Peng D, Han Y, Ding H, Wei L. Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors. J Gastroenterol Hepatol 2008; 23: 1082-88.
  15. Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006;6:1636-42.
  16. Ateş F, Yalnız M, Alan S. Impact of liver steatosis on response to pegylated interferon therapy in patients with chronic hepatitis B. World J Gastroenterol. 2011;17:4517-22.
  17. Cindoruk M, Karakan T, Unal S. Hepatic steatosis has no impact on the outcome of treatment in patients with chronic hepatitis B infection. J Clin Gastroenterol. 2007 ; 41:513-7.
  18. Shi JP, Lu L, Qian JC,et al. Impact of liver steatosis on antiviral effects of pegylated interferon-alpha in patients with chronic hepatitis B. Zhonghua Gan Zang Bing Za Zhi. 2012;20:285-8.